2015
DOI: 10.2174/1574884708666131229124215
|View full text |Cite
|
Sign up to set email alerts
|

Tuberculosis: Challenges to Improve the Treatment

Abstract: Tuberculosis is one of the leading causes of morbidity and mortality worldwide. Current treatment has several challenges, such as multi-drug resistance, extensively drug-resistance and HIV co-infection. Problems related to patients, treatment and health care system also contribute negatively to this panel. This review summarizes the main obstacles causing in the treatment of tuberculosis and discusses several strategies to improve the treatment.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
3
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…The emergence of X/MDR strains (Extensively/multi drug-resistant TB) has complicated the scenario thereby necessitating several groups to focus on newer targets, synthesis of novel compounds and explore natural products that can serve as leads for the design of anti-tubercular drugs (Palomino et al, 2009; Lima et al, 2015; Zumla, 2015). Among the targets, Filamentous temperature-sensitive mutant Z (FtsZ) protein is an essential bacterial protein which comprises of nucleotide binding N and C-terminal domains with the (tubulin)-like synergy loop (T7 loop).…”
Section: Introductionmentioning
confidence: 99%
“…The emergence of X/MDR strains (Extensively/multi drug-resistant TB) has complicated the scenario thereby necessitating several groups to focus on newer targets, synthesis of novel compounds and explore natural products that can serve as leads for the design of anti-tubercular drugs (Palomino et al, 2009; Lima et al, 2015; Zumla, 2015). Among the targets, Filamentous temperature-sensitive mutant Z (FtsZ) protein is an essential bacterial protein which comprises of nucleotide binding N and C-terminal domains with the (tubulin)-like synergy loop (T7 loop).…”
Section: Introductionmentioning
confidence: 99%
“…TB remains a leading cause of morbidity and mortality in many countries. Current anti-TB treatments have several problems, including the development of multidrug resistance and human immunodeficiency virus (HIV) coinfection [ 1 , 2 ]. TB usually affects the lungs but can also affect other parts of the body, such as the brain, intestines, kidneys, and/or the spine [ 3 ].…”
Section: Introductionmentioning
confidence: 99%
“…Despite extensive attempts to control and eradicate TB, it remains a prominent global public health concern. The current drug regime used for TB treatment has many side effects [ 49 ], as well as the emergence of drug-resistant strains further complicates TB control efforts [ 50 ]. This pressing concern demands the development of a novel anti-TB drug, which led us to explore the potential of a probiotic strain, Lactocaseibacillus rhamnosus PMC203, to reduce M. tuberculosis burden through stimulation of autophagy, an essential component of the body’s natural defense system.…”
Section: Discussionmentioning
confidence: 99%